Recent advances in next-generation sequencing (NGS) technologies, increasing cost pressures, and regulatory uncertainties have driven pharmaceutical (pharma) and healthcare business models from curative to preventive. A molecular-level understanding of the root causes of diseases is paramount to developing targeted drugs and companion diagnostics. Affordable DNA sequencing is encouraging companies to switch from traditional to NGS for commercial diagnostic and translational research, thus promoting the adoption and growth of NGS informatics technology and driving precision medicine.
